Apeiron Biologics Spins Off New Mass Spec Research and Dx Firm Attoquant Diagnostics | GenomeWeb

Austrian pharma firm Apeiron Biologics this week launched Attoquant Diagnostics, a subsidiary founded to commercialize and develop the company's RAS-Fingerprint peptide analytics service.

The RAS-Fingerprint product consists of mass spectrometry assays for measuring ten peptides of the renin-angiotensin system, which plays a significant role in regulating processes including blood pressure, water balance, and inflammation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.